AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28839339
Drug: Valbenazine (VBZ)
DrugBank: Valbenazine (DB11915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valbenazine (VBZ) 50 mg once-daily for 8 days (Cohort 2)
Trial: 23876867
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab (3 monthly injections)
Trial: 15488870
Drug: Atorvastatin 10mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10mg/day (A)
Trial: 15488870
Drug: E +
RxNorm normalized name: Perle +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E + Atorvastatin (E + A)
Trial: 11673867
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of o,o'-[(14)C]dityrosine into mice
Trial: 7884017
Drug: Intramuscular zuclopenthixol
RxNorm normalized name: zuclopenthixol
DrugBank: Zuclopenthixol (DB01624)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular zuclopenthixol acetate (50 to 150 mg every 3 days)
Trial: 7884017
Drug: Liquid oral
RxNorm normalized name: M-End Liquid Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid oral haloperidol (10 to 30 mg daily, three times a day)
Trial: 31843270
Drug: Strep A
RxNorm normalized name: Sofia Strep A+ FIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strep A vaccine (StreptAnova™), administered intramuscularly at 0, 30, and 180 days
Trial: 31843270
Drug: Strep A
RxNorm normalized name: Sofia Strep A+ FIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strep A vaccine (StreptAnova™)
Trial: 21279976
Drug: Intravenous pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous pentoxifylline
Trial: 21279976
Drug: Pulse steroid
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse steroid and cyclophosphamide therapy
Trial: 10436756
Drug: SonoVue 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SonoVue 0.3 ml
Trial: 10436756
Drug: SonoVue 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SonoVue 0.6 ml
Trial: 10436756
Drug: SonoVue 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SonoVue 1.2 ml
Trial: 16421404
Drug: SonoVue 2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SonoVue 2.4 ml
Trial: 7372822
Drug: Hypnotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnotic treatment
Trial: 7372822
Drug: Trophotropic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trophotropic treatment
Trial: 31216846
Drug: PIEB 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIEB 10 ml every 60 min (Group 10q60)
Trial: 31216846
Drug: PIEB 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIEB 5 ml every 30 min (Group 5q30)
Trial: 31216846
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion (CEI) 10 ml/h
Trial: 26088268
Drug: Idarucizumab 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarucizumab 1 g
Trial: 26088268
Drug: Idarucizumab 2
RxNorm normalized name: idaruCIZUmab 2.5 GM in 50 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarucizumab 2 g
Trial: 26088268
Drug: Idarucizumab 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarucizumab 4 g
Trial: 26088268
Drug: Idarucizumab 5
RxNorm normalized name: idaruCIZUmab 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarucizumab 5 g plus 2.5 g
Trial: 23104146
Drug: Intravenous ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ondansetron 8 mg
Trial: 21606305
Drug: Hydroxyurea therapy
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea therapy (part of the BABY HUG trial)
Trial: 7685442
Drug: Losartan >
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan > 10 mg
Trial: 2444780
Drug: Nifedipine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (mean dose, 70 mg/day)
Trial: 2444780
Drug: Nitroglycerin patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin patches (mean dose, 16 cm/day)
Trial: 2444780
Drug: Control period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control period (no other antianginal treatment)
Trial: 29764853
Drug: CC-486 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-486 monotherapy (300 mg, every day, days 1-14/21)
Trial: 29764853
Drug: CC-486 in
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-486 in combination with carboplatin (300 mg, every day, days 1-14/21)
Trial: 29764853
Drug: CC-486 in
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-486 in combination with nab-paclitaxel (200 mg, every day, days 1-14/21)
Trial: 29764853
Drug: CC-486 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-486 (various doses)
Trial: 26915749
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (n=109)
Trial: 21592681
Drug: Sertraline (100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (100mg daily)
Trial: 9262265
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of FSH (450 IU i.m.)
Trial: 8365747
Drug: 1.5 x
RxNorm normalized name: lisocabtagene maraleucel 1.5 x 10exp6 to 70 x 10exp6 cell/mL INTRAVEN VIAL (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 x 10(6) units of streptokinase (SK) in 200 ml of normal saline
Trial: 8365747
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml of normal saline alone (control)
Trial: 27595715
Drug: Single-session root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-session root canal treatment (GSS)
Trial: 27595715
Drug: Two-session root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-session root canal treatment with calcium hydroxide intracanal medication (GTS)
Trial: 20628004
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea (6 cups daily for 3 to 6 weeks)
Trial: 16595780
Drug: Low-dose isotretinoin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose isotretinoin (30 mg/day)
Trial: 7171415
Drug: Methadone 10
RxNorm normalized name: normethadone 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone 10 mg i.v. (acute administration)
Trial: 31417958
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy alone
Trial: 24021606
Drug: One specific
RxNorm normalized name: Fruit cone specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One specific physical treatment device using a biorhythmically defined stimulus for vasomotion
Trial: 24021606
Drug: Two other
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two other physical treatment devices
Trial: 24021606
Drug: Three other
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three other physical treatment devices
Trial: 20070133
Drug: Stepped Collaborative
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Stepped Collaborative Care (CC)
Trial: 20070133
Drug: CC (Control)
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC (Control)
Trial: 3129806
Drug: Lithium preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium preparations (lithium carbonate, lithium oxybutyrate)
Trial: 3129806
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and standard antiulcerative therapy
Trial: 23207186
Drug: YGD (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YGD (3 tablets)
Trial: 18629524
Drug: FREMS therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FREMS therapy
Trial: 16582130
Drug: Misoprostol 800
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol 800 mcg vaginally on study day 1, with a repeat dose if indicated on day 3.
Trial: 8858462
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg i.v. at 8 hourly intervals (group 1 and 2)
Trial: 8858462
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg i.v. at 12 hourly intervals (group 3)
Trial: 8858462
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg i.v. at 12 hourly intervals (group 4)
Trial: 1512337
Drug: Captopril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (4 days of therapy)
Trial: 30328569
Drug: Shenzhu Guanxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenzhu Guanxin Recipe Granules (SGR) 10 g/day for 12 weeks
Trial: 27583882
Drug: Collateral Meridian
RxNorm normalized name: sibutramine hydrochloride Oral Capsule [Meridia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collateral Meridian Therapy (CMT)
Trial: 22863159
Drug: Combination aliskiren/hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination aliskiren/hydrochlorothiazide (HCT) 150/12.5 mg
Trial: 22863159
Drug: Aliskiren 150
RxNorm normalized name: aliskiren 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 150 mg (force-titrated to 300/25 mg and 300 mg)
Trial: 20582746
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg 0.2% ropivacaine
Trial: 20582746
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg 0.2% ropivacaine plus 0.5 mg/kg ketamine
Trial: 9813398
Drug: Rifaximin 200
RxNorm normalized name: rifAXIMin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 200 mg t.i.d.
Trial: 9813398
Drug: Rifaximin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin (all doses)
Trial: 26121788
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration therapy (ORT) group, allowed to drink clear liquids until 2 hours before anesthesia induction
Trial: 23241727
Drug: 400 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 µg of misoprostol orally 12 hours before the procedure
Trial: 21939942
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus glycoprotein IIb/IIIa inhibitor (GPI)
Trial: 18652102
Drug: Bupivacaine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (3 ml of isobaric bupivacaine 5 mg/ml)
Trial: 18652102
Drug: Ropivacaine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (3 ml of isobaric ropivacaine 5 mg/ml)
Trial: 18652102
Drug: Levobupivacaine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine (3 ml of isobaric levobupivacaine 5 mg/ml)
Trial: 11163674
Drug: Standard titre
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard titre measles vaccine given at age 9 months
Trial: 11163674
Drug: Standard titre
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard titre measles vaccine given at age 6 months
Trial: 11163674
Drug: Both vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both vaccine groups
Trial: 7820191
Drug: Medrogestone (M)
RxNorm normalized name: medrogestone
DrugBank: Medrogestone (DB09124)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medrogestone (M) at a dose of 10 mg/day from D4 to D24
Trial: 2830642
Drug: Chemotherapy (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (cisplatin 70 mg/m2 i.v. day one, etoposide 100 mg/m2 i.v. day one, 200 mg/m2 orally days 2 and 3, repeated every third week to a maximum of 4 cycles)
Trial: 1385603
Drug: amphetamine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amphetamine (15 mg)
Trial: 1385603
Drug: placebo/amphetamine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo/amphetamine (15 mg)
Trial: 28954882
Drug: Caffeine 200
RxNorm normalized name: caffeine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 200 mg BID for 6-18 months
Trial: 28954882
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules for 6-18 months
Trial: 28954882
Drug: Caffeine 200
RxNorm normalized name: caffeine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 200 mg BID
Trial: 23660738
Drug: PDT delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDT delivered twice within 1 week (group A)
Trial: 23660738
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment without activating the laser (group C)
Trial: 22545106
Drug: 1.7 g
RxNorm normalized name: Vaporizer 1.7 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.7 g of DHA and 0.6 g EPA daily for 6 months
Trial: 7995008
Drug: Quinidine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine monotherapy
Trial: 7995008
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of amiloride (1 mumol/L) and quinidine (10 mumol/L)
Trial: 7995008
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of amiloride and quinidine
Trial: 2574728
Drug: Nifedipine twice
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine twice daily
Trial: 2574728
Drug: Nisoldipine and
RxNorm normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nisoldipine and Nifedipine combined with a beta-blocker
Trial: 10792124
Drug: 10- to
RxNorm normalized name: tolnaftate 10 MG/ML [Blis-To-Sol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10- to 14-day therapies
Trial: 10792124
Drug: 14-day therapies
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day therapies
Trial: 10792124
Drug: 7-day therapies
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day therapies
Trial: 10792124
Drug: 10-day therapies
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day therapies
Trial: 1530319
Drug: Intra-arterial infusion
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusion chemotherapy (I.A.)
Trial: 1530319
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy (I.V.)
Trial: 4018470
Drug: Isosorbide‐5‐mononitrate (IS‐5‐MN;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide‐5‐mononitrate (IS‐5‐MN; 40 mg orally)
Trial: 4018470
Drug: Sustained-release Isosorbide
RxNorm normalized name: isosorbide Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release Isosorbide dinitrate (SRDI; 40 mg orally)
Trial: 25748442
Drug: 5‐MTHF (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐MTHF (5 mM) administered locally via intradermal microdialysis in older adults.
Trial: 25748442
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (5 mg/day) supplementation for 6 weeks in older adults.
Trial: 23863960
Drug: CLEAR regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLEAR regimen (oral levofloxacin, ethambutol, azithromycin, and rifampin)
Trial: 15979246
Drug: Lifetime history
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifetime history of drug treatment
Trial: 15979246
Drug: No history
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No history of drug treatment
Trial: 15979246
Drug: Craving drugs
RxNorm normalized name: BENZALKONIUM CHLORIDE 13 mg in 1 mL TOPICAL SPRAY [Skin Crave non-alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Craving drugs at least 15 days in the past month
Trial: 8839602
Drug: Hypertensive, hypervolemic,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertensive, hypervolemic, hemodilutional therapy (HT)
Trial: 1750429
Drug: Aluminum hydroxide-containing
RxNorm normalized name: Aluminum hydroxide-containing product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminum hydroxide-containing antacid (113 mg per tablet, 2 tablets four times daily)
Trial: 1750429
Drug: Aluminum hydroxide-containing
RxNorm normalized name: Aluminum hydroxide-containing product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminum hydroxide-containing antacid
Trial: 6976617
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (Aspirin), 3000 mg daily
Trial: 6976617
Drug: Fluproquazone, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluproquazone, 300 mg daily
Trial: 31537110
Drug: Nasalance-based preclassification
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasalance-based preclassification of oral-nasal balance disorders
Trial: 31778601
Drug: esomeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: esomeprazole (40 mg/d)
Trial: 31778601
Drug: famotidine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine (40 mg/d)
Trial: 22588377
Drug: Coping Cat
RxNorm normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coping Cat program (cognitive-behavioral therapy; CBT)
Trial: 22092484
Drug: Vitamin trial
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin trial (Vitamin C = 500 mg/day + Vitamin E = 100 IU/day)
Trial: 18852497
Drug: Monitoring as
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monitoring as a form of therapy
Trial: 3964334
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg t.i.d. indometacin
Trial: 3964334
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg t.i.d. acemetacin
Trial: 20082132
Drug: Multi-electrode array
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-electrode array ablation catheters with uninterrupted warfarin
Trial: 20082132
Drug: Uninterrupted aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Uninterrupted aspirin
Trial: 18756743
Drug: Trimetazidine (Preductal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (Preductal MR) in addition to traditional therapy
Trial: 11805921
Drug: Rofecoxib, 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib, 25 mg daily for 5 consecutive days starting 3 days before surgery
Trial: 10715762
Drug: Lignocaine throat
RxNorm normalized name: Sucrets Sore Throat
DrugBank: Dyclonine (DB00645)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lignocaine throat spray only
Trial: 8868980
Drug: Pimobendan 2.5
RxNorm normalized name: pimobendan 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimobendan 2.5 mg daily
Trial: 1595521
Drug: Trapidil (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trapidil (600 mg/day orally for 1 week before PTCA and for 4 to 6 months after PTCA)
Trial: 1595521
Drug: Aspirin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (300 mg/day) and dipyridamole (150 mg/day)
Trial: 6705164
Drug: Ketanserin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (2 mg/hr iv, preceded by a 10 mg bolus in three patients)
Trial: 30145269
Drug: Remote delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote delivery (RD) using video conferencing on a tablet computer
Trial: 26754679
Drug: Pomalidomide 4
RxNorm normalized name: pomalidomide 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide 4 mg
Trial: 26754679
Drug: Pomalidomide 20
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide 20 mg
Trial: 22475889
Drug: Lu AA21004
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lu AA21004 5 or 10 mg/day
Trial: 22475889
Drug: Lu AA21004
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lu AA21004 5 or 10 mg/day (stable responders)
Trial: 20444957
Drug: Plant sterol
RxNorm normalized name: plant sterol complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterol therapy
Trial: 20444957
Drug: Plant sterol
RxNorm normalized name: plant sterol complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterol therapy in mice
Trial: 16231850
Drug: Doxorubicin-based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin-based chemotherapy